Secondary angiosarcomas are aggressive mesenchymal tumors with a poor prognosis and limited
therapeutic options. Recent studies conducted in patients with cutaneous squamous-cell
carcinoma provide evidence that cemiplimab has the potential to be an effective treatment
also for patients with secondary angiosarcomas.
The purpose of this study is to evaluate the overall response rate after 24 weeks of
cemiplimab treatment in patients with locally advanced or metastatic secondary angiosarcomas.
The investigators hypothesis is that cemiplimab could be an effective treatment for patients
diagnosed with locally advanced and metastatic secondary angiosarcomas.